Log In
Print this Print this

ANG1005 (formerly GRN1005)

  Manage Alerts
Collapse Summary General Information
Company Angiochem Inc.
DescriptionPeptide (Angiopep-2) conjugated to 3 paclitaxel molecules for receptor-mediated transport into the brain
Molecular Target Low-density lipoprotein-related protein 1 alpha-2-macroglobulin receptor (LRP1) (CD91) ; Tubulin
Mechanism of ActionMicrotubule stabilization
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationBrain cancer
Indication DetailsTreat advanced solid tumors with brain metastases; Treat brain cancer; Treat brain metastases arising from non-small cell lung cancer (NSCLC); Treat brain metastases arising from metastatic breast cancer; Treat brain metastases from non-small cell lung cancer (NSCLC) and breast cancer; Treat glioblastoma; Treat glioblastoma multiforme (GBM); Treat malignant glioma; Treat recurrent glioma
Regulatory Designation

U.S. - Fast Track (Treat glioblastoma multiforme (GBM));
U.S. - Orphan Drug (Treat glioblastoma multiforme (GBM))


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today